Bio-Gene Technology Tax Expense
The Income Tax Expense of Bio-Gene Technology (BGT.AX) as of Oct 27, 2026 is -469,502.00 AUD. In the previous year, Income Tax Expense was -385,635.00 AUD — a change of 21.75% (lower).
Get this data via API
Financial Data API
Tax Expense
-469,502.00AUD
YoY
21.75%
Last updated:
The Bio-Gene Technology Tax Expense history
3 Years
10 Years
25 Years
Max
| YEAR | Tax Expense | YoY |
|---|---|---|
| -469,502.00AUD | +21.75% | |
| -385,635.00AUD | -36.17% | |
| -604,187.00AUD | +35.51% | |
| -445,846.00AUD | +2.72% | |
| -434,050.00AUD | -14.98% | |
| -510,509.00AUD | +707.15% | |
| -63,248.00AUD | -53.44% | |
| -135,847.00AUD | -70.96% | |
| -467,739.00AUD | +367.74% | |
| -100,000.00AUD | -46.34% | |
| -186,367.00AUD | +134.69% | |
| -79,409.00AUD | +58.30% | |
| -50,163.00AUD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bio-Gene Technology Stock analysis
Frequently Asked Questions about Bio-Gene Technology stock
Income Tax Expense of Bio-Gene Technology is -469,502.00 AUD in 2026.
Income Tax Expense of Bio-Gene Technology changed from -385,635.00 AUD to -469,502.00 AUD, representing a 21.75% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Income Tax Expense Bio-Gene Technology since 2006 – with annual values, charts, and detailed analysis.
Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.
Income Tax Expense's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's Bio-Gene Technology historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Bio-Gene Technology
All Key Metrics — Bio-Gene Technology
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth